Ruey-Hwang Chou - Search Results

Year	Number of Results
2002	2
2004	1
2006	1
2007	1
2009	1
2010	2
2011	4
2012	3
2013	8
2014	7
2015	3
2016	7
2017	4
2018	7
2019	2
2020	7
2021	7
2022	4
2023	1
2024	1

1

The potential roles of EZH2 in regenerative medicine.

Chou RH, Chiu L, Yu YL, Shyu WC. Chou RH, et al. Cell Transplant. 2015;24(3):313-7. doi: 10.3727/096368915X686823. Epub 2015 Feb 2. Cell Transplant. 2015. PMID: 25647295 Free article. Review.

2

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, Chan WP, Chou RH. Yan KS, et al. Among authors: chou rh. Int J Mol Sci. 2017 May 31;18(6):1172. doi: 10.3390/ijms18061172. Int J Mol Sci. 2017. PMID: 28561778 Free PMC article. Review.

3

The potential therapeutic applications of olfactory ensheathing cells in regenerative medicine.

Chou RH, Lu CY; Wei-Lee; Fan JR, Yu YL, Shyu WC. Chou RH, et al. Cell Transplant. 2014;23(4-5):567-71. doi: 10.3727/096368914X678508. Cell Transplant. 2014. PMID: 24816451 Free article. Review.

4

Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis.

Chang LC, Chiang SK, Chen SE, Yu YL, Chou RH, Chang WC. Chang LC, et al. Among authors: chou rh. Cancer Lett. 2018 Mar 1;416:124-137. doi: 10.1016/j.canlet.2017.12.025. Epub 2017 Dec 20. Cancer Lett. 2018. PMID: 29274359

5

S100P Interacts with p53 while Pentamidine Inhibits This Interaction.

Katte RH, Dowarha D, Chou RH, Yu C. Katte RH, et al. Among authors: chou rh. Biomolecules. 2021 Apr 24;11(5):634. doi: 10.3390/biom11050634. Biomolecules. 2021. PMID: 33923162 Free PMC article.

6

Synthesis of Novel Suramin Analogs With Anti-Proliferative Activity via FGF1 and FGFRD2 Blockade.

Parveen N, Lin YL, Chou RH, Sun CM, Yu C. Parveen N, et al. Among authors: chou rh. Front Chem. 2022 Jan 3;9:764200. doi: 10.3389/fchem.2021.764200. eCollection 2021. Front Chem. 2022. PMID: 35047478 Free PMC article.

7

PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs.

Chen CH, Wang BW, Hsiao YC, Wu CY, Cheng FJ, Hsia TC, Chen CY, Wang Y, Weihua Z, Chou RH, Tang CH, Chen YJ, Wei YL, Hsu JL, Tu CY, Hung MC, Huang WC. Chen CH, et al. Among authors: chou rh. Oncogene. 2021 Jul;40(29):4796-4808. doi: 10.1038/s41388-021-01889-0. Epub 2021 Jun 21. Oncogene. 2021. PMID: 34155348 Free PMC article.

8

S100A4 inhibits cell proliferation by interfering with the S100A1-RAGE V domain.

Khan MI, Yuan T, Chou RH, Yu C. Khan MI, et al. Among authors: chou rh. PLoS One. 2019 Feb 19;14(2):e0212299. doi: 10.1371/journal.pone.0212299. eCollection 2019. PLoS One. 2019. PMID: 30779808 Free PMC article.

9

The Anti-Cancer Activity of Pentamidine and Its Derivatives (WLC-4059) Is through Blocking the Interaction between S100A1 and RAGE V Domain.

Parveen N, Chiu WJ, Shen LC, Chou RH, Sun CM, Yu C. Parveen N, et al. Among authors: chou rh. Biomolecules. 2022 Dec 30;13(1):81. doi: 10.3390/biom13010081. Biomolecules. 2022. PMID: 36671465 Free PMC article.

10

Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain.

Khan MI, Dowarha D, Katte R, Chou RH, Filipek A, Yu C. Khan MI, et al. Among authors: chou rh. PLoS One. 2019 May 9;14(5):e0216427. doi: 10.1371/journal.pone.0216427. eCollection 2019. PLoS One. 2019. PMID: 31071146 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

68 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year